메뉴 건너뛰기




Volumn 26, Issue 2, 1999, Pages 303-310

Prognostic indicators in hormone refractory prostate cancer

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; HEMOGLOBIN; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN;

EID: 0032963468     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70070-7     Document Type: Article
Times cited : (22)

References (53)
  • 1
    • 0029811462 scopus 로고    scopus 로고
    • Pain caused by bone metastasis in endocrine-therapy-refractory prostate cancer
    • K. Akakura S. Akimoto J. Shimazaki Pain caused by bone metastasis in endocrine-therapy-refractory prostate cancer J Cancer Res Clin Oncol 122 1996 633 637
    • (1996) J Cancer Res Clin Oncol , vol.122 , pp. 633-637
    • Akakura, K.1    Akimoto, S.2    Shimazaki, J.3
  • 2
    • 0028943667 scopus 로고
    • Tumor doubling time in patients with prostate cancer: Determination of prostate-specific antigen and prostatic acid phosphatase doubling time
    • S. Akimoto M. Masai K. Akakura Tumor doubling time in patients with prostate cancer: Determination of prostate-specific antigen and prostatic acid phosphatase doubling time Eur Urol 27 1995 207 212
    • (1995) Eur Urol , vol.27 , pp. 207-212
    • Akimoto, S.1    Masai, M.2    Akakura, K.3
  • 3
    • 0029991439 scopus 로고    scopus 로고
    • Phase II study of weekly intravenous recombinant humanized anti-p185 HER2/neu monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
    • J. Baselga D. Tripathy J. Mendelsohn Phase II study of weekly intravenous recombinant humanized anti-p185 HER2/neu monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer J Clin Oncol 14 1996 737 744
    • (1996) J Clin Oncol , vol.14 , pp. 737-744
    • Baselga, J.1    Tripathy, D.2    Mendelsohn, J.3
  • 4
    • 0016345864 scopus 로고
    • Comparison of treatments for prostatic cancer using an exponential-type life model relating survival to concomitant information
    • S. Bayard R. Greenberg D. Showalter Comparison of treatments for prostatic cancer using an exponential-type life model relating survival to concomitant information Cancer Chemother Rep 58 1974 845 859
    • (1974) Cancer Chemother Rep , vol.58 , pp. 845-859
    • Bayard, S.1    Greenberg, R.2    Showalter, D.3
  • 5
    • 0018663568 scopus 로고
    • Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate
    • W.R. Berry J. Laszlo E. Cox Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate Cancer 44 1979 763 775
    • (1979) Cancer , vol.44 , pp. 763-775
    • Berry, W.R.1    Laszlo, J.2    Cox, E.3
  • 6
    • 0015973060 scopus 로고
    • An exponential model relating censored survival data and concomitant information for prostatic cancer patients
    • D.P. Byar R. Huse J.C. Bailar An exponential model relating censored survival data and concomitant information for prostatic cancer patients J Natl Cancer Inst 52 1974 321 326
    • (1974) J Natl Cancer Inst , vol.52 , pp. 321-326
    • Byar, D.P.1    Huse, R.2    Bailar, J.C.3
  • 7
    • 0015375422 scopus 로고
    • Carcinoma of the prostate: Prognostic evaluation of certain pathologic features in 208 radical prostatectomies
    • D.P. Byar F.K. Mostofi VACURG Carcinoma of the prostate: Prognostic evaluation of certain pathologic features in 208 radical prostatectomies Cancer 30 1972 5 13
    • (1972) Cancer , vol.30 , pp. 5-13
    • Byar, D.P.1    Mostofi, F.K.2    VACURG3
  • 8
    • 0026021087 scopus 로고
    • Independent prognostic factors in patients with metastatic (stage D2) prostate cancer
    • G.W. Chodak N.J. Vogelzang R.I. Caplan Independent prognostic factors in patients with metastatic (stage D2) prostate cancer JAMA 265 1991 618 621
    • (1991) JAMA , vol.265 , pp. 618-621
    • Chodak, G.W.1    Vogelzang, N.J.2    Caplan, R.I.3
  • 9
    • 0019485158 scopus 로고
    • Systemic treatment of advanced prostatic cancer: Development of a new system for defining response
    • D.L. Citrin A.I. Cohen J. Harberg Systemic treatment of advanced prostatic cancer: Development of a new system for defining response J Urol 125 1981 224 227
    • (1981) J Urol , vol.125 , pp. 224-227
    • Citrin, D.L.1    Cohen, A.I.2    Harberg, J.3
  • 10
    • 0029993112 scopus 로고    scopus 로고
    • Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer
    • A.V. D'Amico R. Whittington S.B. Malkowicz Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer J Clin Oncol 14 1996 1770 1777
    • (1996) J Clin Oncol , vol.14 , pp. 1770-1777
    • D'Amico, A.V.1    Whittington, R.2    Malkowicz, S.B.3
  • 11
    • 0024600990 scopus 로고
    • Univariate analysis of prognostic factors in patients with advanced prostatic cancer: Results from two European organization for research on treatment of cancer trials
    • De Voogt H.J. S. Suciu R. Sylvester Univariate analysis of prognostic factors in patients with advanced prostatic cancer: Results from two European organization for research on treatment of cancer trials J Urol 141 1989 883 888
    • (1989) J Urol , vol.141 , pp. 883-888
    • De Voogt, H.J.1    Suciu, S.2    Sylvester, R.3
  • 12
    • 0018687833 scopus 로고
    • Leukoerythroblastosis and cancer frequency, prognosis and physiologic significance
    • G. Delsol B. Guiu-Godfrin M. Guiu Leukoerythroblastosis and cancer frequency, prognosis and physiologic significance Cancer 44 1979 1009 1013
    • (1979) Cancer , vol.44 , pp. 1009-1013
    • Delsol, G.1    Guiu-Godfrin, B.2    Guiu, M.3
  • 13
    • 0031835943 scopus 로고    scopus 로고
    • European organization for research and treatment of cancer (EORTC) prostate cancer trials, 1976–1996
    • L. Denis European organization for research and treatment of cancer (EORTC) prostate cancer trials, 1976–1996 Urology 51 suppl 5A 1998 50 57
    • (1998) Urology , vol.51 , Issue.suppl 5A , pp. 50-57
    • Denis, L.1
  • 14
    • 0020957960 scopus 로고
    • A comparative clinical trial of Adriamycin and 5-Florouracil in advanced prostatic cancer: Prognostic factors and response
    • W.D. Dewys C.B. Begg H. Brodovsky A comparative clinical trial of Adriamycin and 5-Florouracil in advanced prostatic cancer: Prognostic factors and response Prostate 4 1983 1 11
    • (1983) Prostate , vol.4 , pp. 1-11
    • Dewys, W.D.1    Begg, C.B.2    Brodovsky, H.3
  • 15
    • 0022356273 scopus 로고
    • Prognostic factors in patients with advanced prostate cancer
    • L.J. Emrich R.L. Priore G.P. Murphy Prognostic factors in patients with advanced prostate cancer Cancer Res 45 1985 5173 5179
    • (1985) Cancer Res , vol.45 , pp. 5173-5179
    • Emrich, L.J.1    Priore, R.L.2    Murphy, G.P.3
  • 16
    • 0026548628 scopus 로고
    • Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostate cancer undergoing experimental treatment
    • S.D. Fossa E. Paus M. Lindegaard Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostate cancer undergoing experimental treatment Br J Urol 69 1992 175 179
    • (1992) Br J Urol , vol.69 , pp. 175-179
    • Fossa, S.D.1    Paus, E.2    Lindegaard, M.3
  • 17
    • 17444434615 scopus 로고    scopus 로고
    • Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma
    • R.A. Ghossein J. Rosai H.I. Scher Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma Urology 50 1997 100 105
    • (1997) Urology , vol.50 , pp. 100-105
    • Ghossein, R.A.1    Rosai, J.2    Scher, H.I.3
  • 18
    • 0015950349 scopus 로고
    • Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging
    • D.F. Gleason G.T. Mellinger VACURG Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging J Urol 111 1974 58 64
    • (1974) J Urol , vol.111 , pp. 58-64
    • Gleason, D.F.1    Mellinger, G.T.2    VACURG3
  • 19
    • 0013890366 scopus 로고
    • Classification of prostatic carcinomas
    • D.F. Gleason Classification of prostatic carcinomas Cancer Chemother Rep 50 1966 125 128
    • (1966) Cancer Chemother Rep , vol.50 , pp. 125-128
    • Gleason, D.F.1
  • 20
    • 0030297953 scopus 로고    scopus 로고
    • Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study
    • C.S. Higano W. Ellis K. Russell Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study Urology 48 1996 800 804
    • (1996) Urology , vol.48 , pp. 800-804
    • Higano, C.S.1    Ellis, W.2    Russell, K.3
  • 21
    • 0016721437 scopus 로고
    • Carcinoma of the prostate: Correlation between radiologic quantification of metastases and patient survival
    • J.A. Hovsepian D.P. Byar VACURG Carcinoma of the prostate: Correlation between radiologic quantification of metastases and patient survival Urology 6 1975 11 16
    • (1975) Urology , vol.6 , pp. 11-16
    • Hovsepian, J.A.1    Byar, D.P.2    VACURG3
  • 22
    • 0028808702 scopus 로고
    • Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer
    • G.R. Hudes F.E. Nathan C. Khater Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer Semin Oncol 22 1995 41 45
    • (1995) Semin Oncol , vol.22 , pp. 41-45
    • Hudes, G.R.1    Nathan, F.E.2    Khater, C.3
  • 23
    • 0027944451 scopus 로고
    • Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: A southwest oncology group report
    • M. Hussain M. Wolf E. Marshall Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: A southwest oncology group report J Clin Oncol 12 1994 1868 1875
    • (1994) J Clin Oncol , vol.12 , pp. 1868-1875
    • Hussain, M.1    Wolf, M.2    Marshall, E.3
  • 24
    • 0031745738 scopus 로고    scopus 로고
    • A new parameter for measuring metastatic bone involvement by prostate cancer: The bone scan index
    • M. Imbriaco S.M. Larson H.W. Yeung A new parameter for measuring metastatic bone involvement by prostate cancer: The bone scan index Clin Cancer Res 4 1998 1765 1772
    • (1998) Clin Cancer Res , vol.4 , pp. 1765-1772
    • Imbriaco, M.1    Larson, S.M.2    Yeung, H.W.3
  • 25
    • 0017665658 scopus 로고
    • Alkaline phosphatase in serum of patients with prostatic carcinoma
    • T. Ishibe Alkaline phosphatase in serum of patients with prostatic carcinoma Urology 10 1977 227 232
    • (1977) Urology , vol.10 , pp. 227-232
    • Ishibe, T.1
  • 26
    • 0027511899 scopus 로고
    • Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
    • W.K. Kelly H.I. Scher M. Mazumdar Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer J Clin Oncol 11 1993 607 615
    • (1993) J Clin Oncol , vol.11 , pp. 607-615
    • Kelly, W.K.1    Scher, H.I.2    Mazumdar, M.3
  • 27
    • 0028899680 scopus 로고
    • Staging of prostate cancer: Accuracy of MRI imaging
    • C. Langlotz M. Schnall H. Pollack Staging of prostate cancer: Accuracy of MRI imaging Radiology 194 1995 645 646
    • (1995) Radiology , vol.194 , pp. 645-646
    • Langlotz, C.1    Schnall, M.2    Pollack, H.3
  • 28
    • 0031947670 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer
    • C. Mahler J. Vehelst L. Denis Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer Clin Pharmacokinet 34 1998 405 417
    • (1998) Clin Pharmacokinet , vol.34 , pp. 405-417
    • Mahler, C.1    Vehelst, J.2    Denis, L.3
  • 29
    • 0024218086 scopus 로고
    • Androgen priming and chemotherapy in advanced prostate cancer: Evaluation of determinants of clinical outcome
    • A. Manni M. Bartholomew R. Caplan Androgen priming and chemotherapy in advanced prostate cancer: Evaluation of determinants of clinical outcome J Clin Oncol 6 1988 1456 1466
    • (1988) J Clin Oncol , vol.6 , pp. 1456-1466
    • Manni, A.1    Bartholomew, M.2    Caplan, R.3
  • 30
    • 0026687613 scopus 로고
    • Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer
    • H. Matzkin P. Eber B. Todd Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer Cancer 70 1992 2302 2309
    • (1992) Cancer , vol.70 , pp. 2302-2309
    • Matzkin, H.1    Eber, P.2    Todd, B.3
  • 31
    • 0026525245 scopus 로고
    • The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer
    • J.I. Miller F.R. Ahmann G.W. Drach The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer J Urol 147 1992 956 961
    • (1992) J Urol , vol.147 , pp. 956-961
    • Miller, J.I.1    Ahmann, F.R.2    Drach, G.W.3
  • 32
    • 0030904147 scopus 로고    scopus 로고
    • Assessment of hormone refractory prostate cancer
    • D. Newling S.D. Fossa L. Andersson Assessment of hormone refractory prostate cancer Urology 49 4A suppl 1997 46 53
    • (1997) Urology , vol.49 , Issue.4A suppl , pp. 46-53
    • Newling, D.1    Fossa, S.D.2    Andersson, L.3
  • 33
    • 0030659642 scopus 로고    scopus 로고
    • PSA evolution: A prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade
    • W. Oosterlinck J. Mattelaer J. Casselman PSA evolution: A prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade Acta Urol Belg 65 1997 63 71
    • (1997) Acta Urol Belg , vol.65 , pp. 63-71
    • Oosterlinck, W.1    Mattelaer, J.2    Casselman, J.3
  • 34
    • 0023881932 scopus 로고
    • Prostate-specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy
    • J.E. Osterling D.W. Chan J.I. Epstein Prostate-specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy J Urol 139 1988 766 772
    • (1988) J Urol , vol.139 , pp. 766-772
    • Osterling, J.E.1    Chan, D.W.2    Epstein, J.I.3
  • 35
    • 0030913315 scopus 로고    scopus 로고
    • Combination of prostate-specific antigen, clinical stage, and gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update
    • A.W. Partin M.W. Kattan E.W. Subong Combination of prostate-specific antigen, clinical stage, and gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update JAMA 277 1997 1445 1451
    • (1997) JAMA , vol.277 , pp. 1445-1451
    • Partin, A.W.1    Kattan, M.W.2    Subong, E.W.3
  • 36
    • 0026441567 scopus 로고
    • Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostate cancer treated with single-agent chemotherapy
    • D.P. Petrylak H.I. Scher Z. Li Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostate cancer treated with single-agent chemotherapy Cancer 70 1992 2870 2878
    • (1992) Cancer , vol.70 , pp. 2870-2878
    • Petrylak, D.P.1    Scher, H.I.2    Li, Z.3
  • 37
    • 0028104733 scopus 로고
    • Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate
    • K.J. Pienta B. Redman M. Hussain Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate J Clin Oncol 12 1994 2005 2012
    • (1994) J Clin Oncol , vol.12 , pp. 2005-2012
    • Pienta, K.J.1    Redman, B.2    Hussain, M.3
  • 38
    • 0030782928 scopus 로고    scopus 로고
    • A phase II trial of oral estramustine and oral etoposide in hormone-refractory prostate cancer
    • K.J. Pienta B.G. Redman R. Bandekar A phase II trial of oral estramustine and oral etoposide in hormone-refractory prostate cancer Urology 50 1997 401 407
    • (1997) Urology , vol.50 , pp. 401-407
    • Pienta, K.J.1    Redman, B.G.2    Bandekar, R.3
  • 39
    • 0019523854 scopus 로고
    • Nuclear bone imaging in metastatic cancer of the prostate
    • J.J. Pollen K. Gerber W.L. Ashburn Nuclear bone imaging in metastatic cancer of the prostate Cancer 47 1981 2585 2594
    • (1981) Cancer , vol.47 , pp. 2585-2594
    • Pollen, J.J.1    Gerber, K.2    Ashburn, W.L.3
  • 40
    • 0028298282 scopus 로고
    • Symptomatology of metastatic prostate cancer: Prognostic significance
    • A. Rana G.D. Chisholm H.M. Rashwan Symptomatology of metastatic prostate cancer: Prognostic significance Br J Urol 73 1994 683 686
    • (1994) Br J Urol , vol.73 , pp. 683-686
    • Rana, A.1    Chisholm, G.D.2    Rashwan, H.M.3
  • 41
    • 84873795073 scopus 로고
    • Metastases in bone marrow and myelophthisic anemia from carcinoma of the prostate
    • R.W. Rundles U. Jonsson Metastases in bone marrow and myelophthisic anemia from carcinoma of the prostate Am J Med Sci 218 1949 241 250
    • (1949) Am J Med Sci , vol.218 , pp. 241-250
    • Rundles, R.W.1    Jonsson, U.2
  • 42
    • 0025186406 scopus 로고
    • Trimetrexate in prostatic cancer: Preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease
    • H.I. Scher T. Curley N. Geller Trimetrexate in prostatic cancer: Preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease J Clin Oncol 8 1990 1830 1838
    • (1990) J Clin Oncol , vol.8 , pp. 1830-1838
    • Scher, H.I.1    Curley, T.2    Geller, N.3
  • 43
    • 0028106791 scopus 로고
    • Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatic cancer: A trial with 10-ethyl-deaza-aminopterin
    • P.K. Schultz W.K. Kelly C. Begg Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatic cancer: A trial with 10-ethyl-deaza-aminopterin Urology 44 1994 237 242
    • (1994) Urology , vol.44 , pp. 237-242
    • Schultz, P.K.1    Kelly, W.K.2    Begg, C.3
  • 44
    • 0031012183 scopus 로고    scopus 로고
    • Staging prostate cancer with MR imaging: A combined radiologist-computer system
    • S.E. Seltzer D.J. Getty C.M.C. Tempany Staging prostate cancer with MR imaging: A combined radiologist-computer system Radiology 202 1997 219 226
    • (1997) Radiology , vol.202 , pp. 219-226
    • Seltzer, S.E.1    Getty, D.J.2    Tempany, C.M.C.3
  • 45
    • 0027277127 scopus 로고
    • Leukoerythroblastic anemia in metastatic prostate cancer
    • G.J. Shamdas F.R. Ahmann M.B. Matzner Leukoerythroblastic anemia in metastatic prostate cancer Cancer 71 1993 3594 3600
    • (1993) Cancer , vol.71 , pp. 3594-3600
    • Shamdas, G.J.1    Ahmann, F.R.2    Matzner, M.B.3
  • 46
    • 37049183697 scopus 로고
    • Human breast cancer: Correlation of relapse and survival with amplification of HER-2/neu oncogene
    • D.J. Slamon G.M. Clark S.G. Wong Human breast cancer: Correlation of relapse and survival with amplification of HER-2/neu oncogene Science 235 1987 177 182
    • (1987) Science , vol.235 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.G.3
  • 47
    • 0031832733 scopus 로고    scopus 로고
    • Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
    • D.C. Smith R.L. Dunn M.S. Strawderman Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer J Clin Oncol 16 1998 1835 1843
    • (1998) J Clin Oncol , vol.16 , pp. 1835-1843
    • Smith, D.C.1    Dunn, R.L.2    Strawderman, M.S.3
  • 48
    • 0023834161 scopus 로고
    • Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan
    • M.S. Soloway S.W. Hardeman D. Hickey Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan Cancer 61 1988 195 202
    • (1988) Cancer , vol.61 , pp. 195-202
    • Soloway, M.S.1    Hardeman, S.W.2    Hickey, D.3
  • 49
    • 0028862179 scopus 로고
    • Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy
    • R. Sridhara M.A. Eisenberger V.J. Sinibaldi Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy J Clin Oncol 13 1995 2944 2953
    • (1995) J Clin Oncol , vol.13 , pp. 2944-2953
    • Sridhara, R.1    Eisenberger, M.A.2    Sinibaldi, V.J.3
  • 50
    • 0030000896 scopus 로고    scopus 로고
    • Acid phosphatase: Defining the role in androgen-independent prostate cancer
    • G. Steineck W.K. Kelly M. Mazumdar Acid phosphatase: Defining the role in androgen-independent prostate cancer Urology 47 1996 719 726
    • (1996) Urology , vol.47 , pp. 719-726
    • Steineck, G.1    Kelly, W.K.2    Mazumdar, M.3
  • 51
    • 0032168442 scopus 로고    scopus 로고
    • Current status of intermittent androgen suppression in the treatment of prostate cancer
    • G. Thayer G. Hamilton Current status of intermittent androgen suppression in the treatment of prostate cancer Urology 52 1998 353 359
    • (1998) Urology , vol.52 , pp. 353-359
    • Thayer, G.1    Hamilton, G.2
  • 52
    • 0027311893 scopus 로고
    • Prostate-specific antigen: An important marker for prostate cancer treated by external beam radiation therapy
    • Zagars G.K. von Eschenbach A.C. Prostate-specific antigen: An important marker for prostate cancer treated by external beam radiation therapy Cancer 72 1993 538 548
    • (1993) Cancer , vol.72 , pp. 538-548
    • Zagars, G.K.1    von Eschenbach, A.C.2
  • 53
    • 0029995206 scopus 로고    scopus 로고
    • Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease
    • A.L. Zietman K.C. Dallow P.A. McManus Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease Urology 47 1996 236 239
    • (1996) Urology , vol.47 , pp. 236-239
    • Zietman, A.L.1    Dallow, K.C.2    McManus, P.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.